ARTICLE | Clinical News

Consortium publishes liver tox markers

June 3, 2009 1:03 AM UTC

FDA and the International Serious Adverse Events Consortium (SAEC) published in Nature Genetics the results of a genomewide association study that showed patients carrying at least one copy of the HLA-B 5701 allele were 80-100 times more likely than non-carriers to develop flucloxacillin-induced liver injury. According to the study, despite being at substantially higher risk than non-carriers, only a small proportion of carriers actually develop liver problems in response to flucloxacillin. The researchers said further research will be needed to determine whether a clinically useful biomarker test could be developed for this susceptibility. The study included 51 patients with flucloxacillin-induced liver injury and 282 controls. ...